Invasive candidiasis as a cause of sepsis in the critically ill patient.
Détails
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_773671C6D430
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Invasive candidiasis as a cause of sepsis in the critically ill patient.
Périodique
Virulence
ISSN
2150-5608 (Electronic)
ISSN-L
2150-5594
Statut éditorial
Publié
Date de publication
2014
Volume
5
Numéro
1
Pages
161-169
Langue
anglais
Notes
Publication types: REVIEWPublication Status: ppublishDocument Type: Review
Résumé
Invasive fungal infections are an increasingly frequent etiology of sepsis in critically ill patients causing substantial morbidity and mortality. Candida species are by far the predominant agent of fungal sepsis accounting for 10% to 15% of health-care associated infections, about 5% of all cases of severe sepsis and septic shock and are the fourth most common bloodstream isolates in the United States. One-third of all episodes of candidemia occur in the intensive care setting. Early diagnosis of invasive candidiasis is critical in order to initiate antifungal agents promptly. Delay in the administration of appropriate therapy increases mortality. Unfortunately, risk factors, clinical and radiological manifestations are quite unspecific and conventional culture methods are suboptimal. Non-culture based methods (such as mannan, anti-mannan, β-d-glucan, and polymerase chain reaction) have emerged but remain investigational or require additional testing in the ICU setting. Few prophylactic or pre-emptive studies have been performed in critically ill patients. They tended to be underpowered and their clinical usefulness remains to be established under most circumstances. The antifungal armamentarium has expanded considerably with the advent of lipid formulations of amphotericin B, the newest triazoles and the echinocandins. Clinical trials have shown that the triazoles and echinocandins are efficacious and well tolerated antifungal therapies. Clinical practice guidelines for the management of invasive candidiasis have been published by the European Society for Clinical Microbiology and Infectious Diseases and the Infectious Diseases Society of North America.
Pubmed
Web of science
Création de la notice
07/03/2014 20:37
Dernière modification de la notice
20/08/2019 15:34